APAC Checkpoint Inhibitors Market

APAC Checkpoint Inhibitors Market Size (2022 to 2027)

The size of the Asia Pacific Checkpoint Inhibitors Market was valued at USD 2.61 billion in 2022. It is projected to reach USD 9.61 billion by 2027, growing at a CAGR of 29.8% from 2022 to 2027.

Due to an increase in the incidence of many types of cancer, more awareness of checkpoint inhibitors for cancer treatment, a higher number of pipeline medications, and increased use of immune checkpoint inhibitor drugs, checkpoint inhibitors have seen increased demand. In addition, the market for Asia Pacific checkpoint inhibitors is predicted to rise due to the adoption of unhealthy lifestyles, rising cancer cases, and genetic modification/alteration. Furthermore, the checkpoint inhibitors market is growing due to a rise in cancer prevalence across geographies and increased awareness of checkpoint inhibitors. Furthermore, technical developments in cancer screening procedures, rising healthcare expenses, more significant government measures to combat cancer, and increased public awareness are projected to propel the market forward.

Furthermore, the market is driven by the growing elderly population and technological developments in cancer screening and detection. In the market for checkpoint inhibitors, there is fierce rivalry, which is pushing acquisitions and in-licensing deals. The top checkpoint inhibitors market players are attempting to diversify and grow their product portfolios. Furthermore, firms are forging partnerships to combine their efforts to produce combination medicines. Several small firms are attempting to tap into the checkpoint inhibitors market's potential by developing next-generation checkpoint inhibitors therapies. The checkpoint inhibitors market is expected to grow during the forecast period due to the increased number of patients, raising public awareness, and earlier cancer detection utilizing technologically enhanced screening technologies.

However, the high cost of product research and development raises the cost of the finished product and associated therapy. This factor is projected to stifle the checkpoint inhibitors market's growth. Furthermore, regulatory price caps have been imposed due to the high cost of checkpoint inhibitors. The lack of cost-effective cancer medicines has influenced the population's health and resulted in a low average life expectancy. The checkpoint inhibitors market is restrained by advancements in cancer therapy and an increase in the population with immune system diseases. Still, strict FDA requirements for new drug approval and adverse effects would hurdle to market expansion. The checkpoint inhibitor market is also projected to be hampered by regulatory price controls for checkpoint inhibitors.

This research report on the Asia Pacific checkpoint inhibitors market has been segmented and sub-segmented into the following categories.

By Drug: 

• PD-1 inhibitors
• PD-L1 inhibitors
• CTLA-4
• Chimeric Antigen Receptor T-cell
• Others

By Application: 

• Lung cancer
• Renal cancer
• Blood cancer
• Bladder Cancer
• Hodgkin lymphoma
• Melanoma
• Others

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, due to the numerous research collaborations between international players and companies from this region, Asia Pacific is the fastest expanding region in the checkpoint inhibitors market worldwide. Furthermore, due to its large population base, increased awareness of advanced immunotherapy increased cancer incidence, and improved healthcare infrastructure, Asia-Pacific presents lucrative opportunities for key players in the checkpoint inhibitors market.

The high prevalence of cancer in China, Japan, and India is projected to fuel demand for immunological checkpoint inhibitors in the near future. In addition, the presence of major key players and significant investment in R&D activities to develop new products with fewer side effects and generic drugs, as well as government incentives to encourage innovation to reduce the growing disease burden, are likely to provide more opportunities for the ICI market to grow during the forecast period.

KEY MARKET PLAYERS:

Companies playing a vital role in the Asia Pacific checkpoint inhibitors market profiled in this report are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.